

Yao Chi Chuang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3098384/yao-chi-chuang-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

3,169
citations

32
h-index

51
g-index

142
ext. papers

3,722
ext. citations

2.9
avg, IF

5.2
L-index

#	Paper	IF	Citations
136	Response to a Letter to Editor for article "Impacts of nocturia on quality of life, mental health, work limitation, and health care seeking in China, Taiwan and South Korea (LUTS Asia): Results from a cross-sectional, population-based study".. <i>Journal of the Formosan Medical Association</i> , 2022 , 121, 1016-1016	3.2	
135	Prevalence and impacts of male urinary incontinence on quality of life, mental health, work limitation, and health care seeking in China, Taiwan, and South Korea (LUTS Asia): Results from a cross-sectional, population-based study.. <i>Investigative and Clinical Urology</i> , 2022 , 63, 71-82	1.9	
134	Effects of TORS-OSA Surgery on Lower Urinary Tract Symptoms, Overactive Bladder Symptoms, and Nocturia in Male Patients with Obstructive Sleep Apnea/Hypopnea Syndrome.. <i>Nature and Science of Sleep</i> , 2022 , 14, 547-556	3.6	0
133	The Prognostic Impact of Tumor Location in pT3N0M0 Upper Urinary Tract Urothelial Carcinoma: A Retrospective Cohort Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 850874	5.3	0
132	Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS/PI3K/AKT/eNOS pathway in fructose-fed rats. <i>Scientific Reports</i> , 2021 , 11, 8202	4.9	2
131	Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. <i>Scientific Reports</i> , 2021 , 11, 7558	4.9	2
130	Comparative safety review of current pharmacological treatments for interstitial cystitis/ bladder pain syndrome. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1049-1059	4.1	0
129	Impacts of nocturia on quality of life, mental health, work limitation, and health care seeking in China, Taiwan and South Korea (LUTS Asia): Results from a cross-sectional, population-based study. <i>Journal of the Formosan Medical Association</i> , 2021 , 121, 285-285	3.2	3
128	Low Energy Shock Wave Therapy Attenuates Mitochondrial Dysfunction and Improves Bladder Function in HCl induced Cystitis in Rats. <i>Biomedical Journal</i> , 2021 ,	7.1	2
127	A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021 , 13, 108-117	1.9	0
126	Lifestyle and behavioral modifications made by patients with interstitial cystitis. <i>Scientific Reports</i> , 2021 , 11, 3055	4.9	2
125	The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 613696	5.3	1
124	Interstitial cystitis/bladder pain syndrome patient is associated with subsequent increased risks of outpatient visits and hospitalizations: A population-based study. <i>PLoS ONE</i> , 2021 , 16, e0256800	3.7	0
123	Extracorporeal Shock Wave Enhances the Cisplatin Efficacy by Improving Tissue Infiltration and Cellular Uptake in an Upper Urinary Tract Cancer Animal and Human-Derived Organoid Model. <i>Cancers</i> , 2021 , 13,	6.6	1
122	COVID-19 pandemic impact on urology residencies in Asia - An observational study. <i>Surgical Practice</i> , 2021 , 25, 10-15	0.4	1
121	Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome-A prospective, multicenter, randomized, double-blind, placebo-controlled study. <i>Neurourology and Urodynamics</i> , 2020 , 39, 1505-1514	2.3	12
120	The prevalence of urinary incontinence in men and women aged 40 years or over in China, Taiwan and South Korea: A cross-sectional, prevalence-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020 , 12, 223-234	1.9	6

119	Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan-Japan UTUC Collaboration Cohort. <i>International Journal of Urology</i> , 2020 , 27, 327-332	2.3	6
118	Therapeutic Efficacy of onabotulinumtoxinA Delivered Using Various Approaches in Sensory Bladder Disorder. <i>Toxins</i> , 2020 , 12,	4.9	3
117	New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome - Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave. <i>International Neurourology Journal</i> , 2020 , 24, 211-221	2.6	7
116	Reply to the Commentary on "New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave". <i>International Neurourology Journal</i> , 2020 , 24, 389-390	2.6	
115	Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. <i>Journal of the Chinese Medical Association</i> , 2020 , 83, 55-59	2.8	2
114	The role of intravesical prostatic protrusion in the evaluation of overactive bladder in male patients with LUTS. <i>International Urology and Nephrology</i> , 2020 , 52, 815-820	2.3	1
113	Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13537	2.9	
112	Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	8
111	Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model. <i>International Urology and Nephrology</i> , 2019 , 51, 617-626	2.3	3
110	Risks of interstitial cystitis among patients with systemic lupus erythematosus: A population-based cohort study. <i>International Journal of Urology</i> , 2019 , 26, 897-902	2.3	12
109	Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome. <i>Toxins</i> , 2019 , 11,	4.9	2
108	Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate ketamine-induced cystitis by modulating neuroreceptors, inflammatory mediators, and fibrogenesis in a rat model. <i>Neurourology and Urodynamics</i> , 2019 , 38, 2159-2169	2.3	8
107	Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, 48-55	1.9	36
106	Effect of lower urinary tract symptoms on the quality of life and sexual function of males in China, Taiwan, and South Korea: Subgroup analysis of a cross-sectional, population-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, O78-O84	1.9	8
105	The prevalence and bother of lower urinary tract symptoms in men and women aged 40 years or over in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 170-178	3.2	11
104	Potential Orphan Drug Therapy of Intravesical Liposomal Onabotulinumtoxin-A for Ketamine-Induced Cystitis by Mucosal Protection and Anti-inflammation in a Rat Model. <i>Scientific Reports</i> , 2018 , 8, 5795	4.9	9
103	Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018 , 10, 3-11	1.9	25
102	Risk of Urinary Tract Carcinoma among Subjects with Bladder Pain Syndrome/Interstitial Cystitis: A Nationwide Population-Based Study. <i>BioMed Research International</i> , 2018 , 2018, 7495081	3	6

101	Efficacy and persistence of low-dose mirabegron (25mg) in patients with overactive bladder: analysis in a real-world urological practice. <i>International Urology and Nephrology</i> , 2018 , 50, 1219-1226	2.3	6
100	Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy. <i>Neurourology and Urodynamics</i> , 2018 , 37, 708-715	2.3	7
99	Extracorporeal Shockwave Therapy Assisted Intravesical Drug Delivery. <i>Translational Research in Biomedicine</i> , 2018 , 117-126	0.1	1
98	The prevalence and risk factors of nocturia in China, South Korea, and Taiwan: results from a cross-sectional, population-based study. <i>World Journal of Urology</i> , 2018 , 36, 1853-1862	4	12
97	Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence. <i>International Journal of Urology</i> , 2018 , 25, 615-620	2.3	8
96	A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2017 , 198, 376-382	2.5	36
95	Effects of low energy shock wave therapy on inflammatory moleculars, bladder pain, and bladder function in a rat cystitis model. <i>Neurourology and Urodynamics</i> , 2017 , 36, 1440-1447	2.3	25
94	Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study. <i>BMC Urology</i> , 2017 , 17, 108	2.2	21
93	Potential applications of low-energy shock waves in functional urology. <i>International Journal of Urology</i> , 2017 , 24, 573-581	2.3	24
92	Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study. <i>Advances in Therapy</i> , 2017 , 34, 1953-1965	4.1	60
91	Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F548-54	4.3	10
90	Nocturia indicates a poor health status and increases mortality in male patients with type 2 diabetes mellitus. <i>International Urology and Nephrology</i> , 2016 , 48, 1209-1214	2.3	12
89	The prevalence and predictors of androgen deficiency in Taiwanese men with lower urinary tract symptoms. <i>Urological Science</i> , 2016 , 27, 83-85	0.3	1
88	Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. <i>International Urology and Nephrology</i> , 2016 , 48, 993-9	2.3	24
87	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. <i>Journal of Urology</i> , 2016 , 196, 599-608	2.5	27
86	Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate cyclophosphamide-induced ongoing bladder overactivity and acidic adenosine triphosphate solution-induced hyperactivity on rats prestimulated bladder. <i>Journal of Ethnopharmacology</i> , 2016 , 184, 1-9	5	15
85	Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 521-9	5.9	18
84	Diabetes and Other Neurogenic Underactive Bladder Conditions 2016 , 163-176		

83	Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality. <i>Toxins</i> , 2016 , 8,	4.9	14
82	Determine of the optimal number of cycles of Docetaxel in the treatment of metastatic castration-resistant prostate cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2016 , 32, 458-63	2.4	3
81	Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/interstitial cystitis: a nationwide population-based study. <i>International Urology and Nephrology</i> , 2015 , 47, 275-81	2.3	43
80	Pharmacologic and Molecular Characterization of Underactive Bladder Induced by Lumbar Canal Stenosis. <i>Urology</i> , 2015 , 85, 1284-90	1.6	7
79	Role of liposome in treatment of overactive bladder and interstitial cystitis. <i>Urological Science</i> , 2015 , 26, 3-6	0.3	7
78	Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1612-7	3.1	5
77	Underactive Bladder in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2015 , 31, 523-33	3.8	15
76	Mechanism of action of onabotulinumtoxinA on lower urinary tract dysfunction. <i>Tzu Chi Medical Journal</i> , 2014 , 26, 1-4	1.1	2
75	Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome. <i>BJU International</i> , 2014 , 113, E144-9	5.6	37
74	Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. <i>Journal of Urology</i> , 2014 , 192, 1743-9	2.5	65
73	Prevalence and associated risk factors of nocturia and subsequent mortality in 1,301 patients with type 2 diabetes. <i>International Urology and Nephrology</i> , 2014 , 46, 1269-75	2.3	26
72	The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. <i>Journal of the Formosan Medical Association</i> , 2014 , 113, 506-12	3.2	14
71	Functional and molecular characterization of hyposensitive underactive bladder tissue and urine in streptozotocin-induced diabetic rat. <i>PLoS ONE</i> , 2014 , 9, e102644	3.7	24
70	Non-bladder conditions in female Taiwanese patients with interstitial cystitis/hypersensitive bladder syndrome. <i>International Journal of Urology</i> , 2014 , 21, 805-9	2.3	13
69	Oncological impact of endoscopic bladder cuff management during nephroureterectomy varies according to upper urinary tract tumor location. <i>International Journal of Urology</i> , 2014 , 21, 366-9	2.3	9
68	Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: a single-center study. <i>European Urology</i> , 2014 , 65, 1117-24	10.2	78
67	Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. <i>International Urology and Nephrology</i> , 2014 , 46, 871-7	2.3	33
66	Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer. <i>International Urology and Nephrology</i> , 2014 , 46, 921-6	2.3	21

65	Update in the Use of Botulinum Toxin for the Treatment of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms. <i>Current Bladder Dysfunction Reports</i> , 2013 , 8, 174-179	0.4	1
64	Intravesical drug delivery for dysfunctional bladder. <i>International Journal of Urology</i> , 2013 , 20, 552-62	2.3	32
63	Diagnostic ureteroscopy independently correlates with intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3121-6	3.1	44
62	Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?. <i>International Urology and Nephrology</i> , 2013 , 45, 113-9	2.3	9
61	Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. <i>Journal of the Formosan Medical Association</i> , 2013 , 112, 276-82	3.2	19
60	Medical diseases affecting lower urinary tract function. <i>Urological Science</i> , 2013 , 24, 41-45	0.3	10
59	The prevalence and predictors of androgen deficiency in Taiwanese men with type 2 diabetes. <i>Urology</i> , 2013 , 82, 124-9	1.6	15
58	Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure. <i>Journal of Urology</i> , 2013 , 189, 1553-8	2.5	18
57	Severity of hydronephrosis correlates with tumour invasiveness and urinary bladder recurrence of ureteric cancer. <i>BJU International</i> , 2013 , 112, 489-94	5.6	6
56	OnobotulinumtoxinA Has No Effects on Growth of LNCaP and PC3 Human Prostate Cancer Cells. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2013 , 5, 168-72	1.9	4
55	Albuminuria is an independent risk factor of erectile dysfunction in men with type 2 diabetes. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1055-64	1.1	23
54	The presence of overactive bladder wet increased the risk and severity of erectile dysfunction in men with type 2 diabetes. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1913-22	1.1	15
53	Pathophysiology of Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012 , 4 Suppl 1, 48-55	1.9	37
52	Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin E2-induced bladder overactivity in rats. <i>BJU International</i> , 2012 , 110, 1558-64	5.6	16
51	Intravesical therapy for lower urinary tract symptoms. <i>Urological Science</i> , 2012 , 23, 70-77	0.3	12
50	High-intensity diode laser in combination with bipolar transurethral resection of the prostate: a new strategy for the treatment of large prostates (>80 ml). <i>Lasers in Surgery and Medicine</i> , 2012 , 44, 699-704	3.6	17
49	Sensory dysfunction of bladder mucosa and bladder oversensitivity in a rat model of metabolic syndrome. <i>PLoS ONE</i> , 2012 , 7, e45578	3.7	34
48	1370 URINE ANALYSIS OF CONFIRMED UTI PATIENTS REVEAL HIGHER LEVELS OF CXC CHEMOKINES COMPARED TO PATIENTS WITH LUTS WITHOUT UTI. <i>Journal of Urology</i> , 2011 , 185,	2.5	1

47	Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. <i>Kaohsiung Journal of Medical Sciences</i> , 2011 , 27, 437-40	2.4	24
46	Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. <i>Urology</i> , 2011 , 78, 1040-5	1.6	72
45	Pathophysiological studies of overactive bladder and bladder motor dysfunction in a rat model of metabolic syndrome. <i>Journal of Urology</i> , 2011 , 186, 318-25	2.5	26
44	Twisting maneuver for sutureless vitrectomy trocar insertion to reduce intraoperative intraocular pressure rise. <i>Retina</i> , 2011 , 31, 887-92	3.6	5
43	Application of resonance metallic stents for ureteral obstruction. <i>BJU International</i> , 2011 , 108, 428-32	5.6	59
42	Efficacy and safety of photoselective vaporization of the prostate in patients with prostatic obstruction induced by advanced prostate cancer. <i>Asian Journal of Surgery</i> , 2011 , 34, 135-9	1.6	
41	Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma. <i>International Urology and Nephrology</i> , 2011 , 43, 1067-71	2.3	12
40	Development of cellular therapy for the treatment of stress urinary incontinence. <i>International Urogynecology Journal</i> , 2011 , 22, 1075-83	2	32
39	Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. <i>Neurourology and Urodynamics</i> , 2011 , 30, 421-7	2.3	29
38	1954 AGE ASSOCIATED CHANGES IN URINARY PROTEOME OF OAB PATIENTS. <i>Journal of Urology</i> , 2011 , 185,	2.5	2
37	Is hand-assisted retroperitoneoscopic nephroureterectomy better than transurethral bladder cuff incision-assisted nephroureterectomy?. <i>Journal of Endourology</i> , 2011 , 25, 1307-13	2.7	9
36	Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. <i>BJU International</i> , 2010 , 105, 668-72	5.6	20
35	Expression of E-series prostaglandin (EP) receptors and urodynamic effects of an EP4 receptor antagonist on cyclophosphamide-induced overactive bladder in rats. <i>BJU International</i> , 2010 , 106, 1782-7	5.6	22
34	Botulinum toxin for the lower urinary tract. <i>BJU International</i> , 2010 , 105, 1046-58	5.6	21
33	Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms. <i>Urological Science</i> , 2010 , 21, 132-136	0.3	29
32	Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser. <i>Urology</i> , 2010 , 75, 658-63	1.6	36
31	1590 DISCRIMINATION OF OAB FROM IC/PBS BY MULTIVARIATE DATA MODELING OF URINARY PROTEINS. <i>Journal of Urology</i> , 2010 , 183,	2.5	1
30	GreenLight HPS laser 120-W versus diode laser 200-W vaporization of the prostate: comparative clinical experience. <i>Lasers in Surgery and Medicine</i> , 2010 , 42, 624-9	3.6	46

29 Application of Botulinum Toxin in the Prostate **2009**, 273-282.e1

28 Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. *European Urology*, **2009**, 56, 159-66 10.2 70

27 Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer. *BJU International*, **2009**, 104, 1620-3 5.6 12

26 Bladder Botulinum Toxin. *LUTS: Lower Urinary Tract Symptoms*, **2009**, 1, S22-S25 1.9 1

25 Localized Effects of Antimuscarinics in the Bladder. *LUTS: Lower Urinary Tract Symptoms*, **2009**, 1, S56-S58.9

24 Bladder Instillation of Liposomes for Bladder Coating and Drug Delivery Platform. *LUTS: Lower Urinary Tract Symptoms*, **2009**, 1, S90-S93 1.9 2

23 Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. *Journal of Urology*, **2009**, 182, 786-92 2.5 92

22 Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. *Journal of Urology*, **2009**, 182, 1393-400 2.5 75

21 Treatment of painful bladder syndrome and pelvic organ prolapse: highlights of the 4th international consultation on incontinence, july 5-8, 2008, paris, france. *Reviews in Urology*, **2009**, 11, 28-32 1

20 Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. *BJU International*, **2008**, 102, 704-6 5.6 38

19 Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. *Journal of Urology*, **2008**, 180, 742-8 2.5 72

18 EFFECTS OF BOTULINUM TOXIN A ON SNAP25 LEVEL AND BLADDER FUNCTION IN A CYCLOPHOSPHAMIDE INDUCED CYSTITIS MODEL IN RATS. *Journal of Urology*, **2008**, 179, 61-61 2.5 2

17 Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. *International Urogynecology Journal*, **2008**, 19, 1353-7 2 30

16 Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. *European Urology*, **2007**, 51, 1119-27 10.2 62

15 The application of botulinum toxin in the prostate. *Journal of Urology*, **2006**, 176, 2375-82 2.5 72

14 Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. *Journal of Urology*, **2006**, 175, 1158-63 2.5 120

13 Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. *BMC Urology*, **2006**, 6, 12 2.2 66

12 The potential and promise of using botulinum toxin in the prostate gland. *BJU International*, **2006**, 98, 28-32 5.6 26

11	Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. <i>BJU International</i> , 2006 , 98, 1033-7; discussion 1337	5.6	90
10	Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. <i>Urology</i> , 2005 , 65, 804-10	1.6	21
9	Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. <i>Urology</i> , 2005 , 66, 775-9	1.6	100
8	High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. <i>International Journal of Urology</i> , 2004 , 11, 152-8	2.3	15
7	Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. <i>Journal of Urology</i> , 2004 , 172, 1529-32	2.5	211
6	Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA. <i>Journal of Urology</i> , 2003 , 170, 2044-8	2.5	28
5	Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. <i>Urology</i> , 2003 , 61, 664-70	1.6	57
4	Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. <i>Urology</i> , 2003 , 61, 656-63	1.6	71
3	Botulinum toxin treatment of urethral and bladder dysfunction. <i>Journal of the Formosan Medical Association</i> , 2003 , 102, 5-11	3.2	4
2	Autologous primary muscle-derived cells transfer into the lower urinary tract. <i>Tissue Engineering</i> , 2001 , 7, 395-404		49
1	THE ROLE OF BLADDER AFFERENT PATHWAYS IN BLADDER HYPERACTIVITY INDUCED BY THE INTRAVESICAL ADMINISTRATION OF NERVE GROWTH FACTOR. <i>Journal of Urology</i> , 2001 , 165, 975-979	2.5	122